Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-4718 with Gemcitabine and Nab-paclitaxel in Advanced Cancer
NCT02651727Phase 1Terminated
- Sponsor
- Verastem Oncology
- Start
- Sep 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VS-4718 in pancreatic adenocarcinoma (PDAC) and solid tumor (advanced stage) (3 arms), sponsored by Verastem Oncology. Primary endpoint: Incidence of dose-limiting toxicities at 6 months. Started Sep 2015; status: terminated.
02
Drugs
VS-4718
03
Conditions
pancreatic adenocarcinoma (PDAC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02651727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651727.